Table 3 Sensitivity of the marker panel GHSR/MAL in different subgroups of patients with bladder cancer

All (n = 108)

80 (71–87)

WHO 1973

< 0.001

G1-G2 (n = 56)

66 (52–78)

G3 (n = 52)

96 (85–99)

WHO 2004/2016

< 0.001

LG (n = 45)

58 (42–72)

HG (n = 63)

97 (88–99)

Tumour stage

0.007

Ta/T1/Tis (n = 85)

75 (64–84)

 ≥ T2 (n = 23)

100 (82–100)

Primary/recurrence

< 0.001

Primary (n = 76)

89 (80–95)

Recurrence (n = 32)

59 (41–76)

Gender

0.001

Male (n = 79)

89 (79–94)

Female (n = 29)

59 (39–76)